title: Cytotoxic Activity of Peripheral Blood Mononuclear Leukocytes, Activated by Interleukin-2/β-Cyclodextrin Nanocomposition against Androgen Receptor-Negative Prostate Cancers.
abstract: Nanocomposition comprised of interleukin-2 in suboptimal noneffective concentration and β-cyclodextrin was studied in vitro. This preparation as well as interleukin-2 in optimal concentration was shown to increase natural killer activity to K-562 cells and cytotoxicity of activated peripheral blood mononuclear cells (PBMCs) against PC-3 and DU 145 cells. At the same time β-cyclodextrin or interleukin-2 in equimolar concentrations did not influence the spontaneous killer activity of PBMC. This combination of cyclodextrin + interleukin-2 led to the decrease of interleukin-2 effective concentration by an order. This phenomenon could be explained by cyclodextrins ability to promote the formation of nanoparticles with drugs, which results in enhancing their water solubility and bioavailability. Besides, interleukine-2/β-cyclodextrin nanocomposition as opposed to interleukin-2 alone led to increasing the number of not only lymphocytes, but also macrophages contained in activated PBMC population. Application of low concentration of interleukin-2 allowing for good clinical efficiency may significantly mitigate the side effects of the drug and enable to develop adoption of immunotherapy for patients with androgen-resistant prostate cancer.
authors.affiliation: N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Kashirskoe Shosse, 24, Moscow 115478, Russia.
authors.forename: Natalia Yu
authors.initials: NY
authors.lastname: Anisimova
authors.forename: Andrey V
authors.initials: AV
authors.lastname: Sosnov
authors.forename: Nadezhda E
authors.initials: NE
authors.lastname: Ustyuzhanina
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Baronzio
authors.forename: Mikhail V
authors.initials: MV
authors.lastname: Kiselevsky
references.citation: Arch Immunol Ther Exp (Warsz). 2007 Sep-Oct;55(5):281-7
references.pmid: 18219758
references.citation: Cell Immunol. 1997 Aug 25;180(1):70-83
references.pmid: 9316641
references.citation: Curr Opin Urol. 2007 May;17(3):175-81
references.pmid: 17414515
references.citation: J Cancer Res Clin Oncol. 1991;117(2):109-14
references.pmid: 2007609
references.citation: Clin Immunol. 2000 Sep;96(3):252-63
references.pmid: 10964544
references.citation: Future Oncol. 2009 Mar;5(2):187-96
references.pmid: 19284377
references.citation: Prostate. 2004 Aug 1;60(3):197-204
references.pmid: 15176049
references.citation: J Immunother Emphasis Tumor Immunol. 1995 Jan;17(1):62-8
references.pmid: 7728307
references.citation: Eur J Pharm Biopharm. 2006 Jun;63(2):79-86
references.pmid: 16527473
references.citation: Rev Recent Clin Trials. 2007 Sep;2(3):182-90
references.pmid: 18474004
references.citation: Genet Vaccines Ther. 2008 Jan 18;6:2
references.pmid: 18205933
references.citation: Curr Opin Investig Drugs. 2008 Oct;9(10):1089-94
references.pmid: 18821471
references.citation: Int J Cancer. 2000 Jan 1;85(1):60-7
references.pmid: 10585584
references.citation: Drug Deliv. 2005 Sep-Oct;12(5):281-7
references.pmid: 16188727
references.citation: BioDrugs. 2001;15(11):705-11
references.pmid: 11707145
references.citation: J Immunol. 2007 Oct 1;179(7):4424-34
references.pmid: 17878338
references.citation: Biomaterials. 2009 Jan;30(3):374-82
references.pmid: 18930312
references.citation: Clin Cancer Res. 2000 May;6(5):1632-8
references.pmid: 10815880
references.citation: Cell Immunol. 1995 Apr 1;161(2):256-61
references.pmid: 7697736
references.citation: Int J Pharm. 1999 Jun 10;183(1):33-6
references.pmid: 10361150
references.citation: Jpn J Clin Oncol. 2005 Nov;35(11):690-1
references.pmid: 16306486
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387